Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ocaliva
Pharma
Alfasigma to take over struggling Intercept
The company inked the buyout after two FDA rejections for Ocaliva in NASH-related liver fibrosis and a recent attempt at cutting costs.
Zoey Becker
Sep 26, 2023 11:10am
NASH market holds 'enormous untapped potential,' analysts say
Aug 10, 2023 10:00am
UPDATED: Intercept restructures as NASH hopes dashed by FDA
Jun 22, 2023 6:20pm
Intercept still has a long road ahead with Ocaliva in NASH
May 19, 2023 5:29pm
Intercept's NASH bid in jeopardy after bleak FDA review
May 17, 2023 1:05pm
FDA calls AdComm for Intercept's NASH drug application
Mar 10, 2023 11:18am